Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Flowtuss
×
Overview
What is Flowtuss?
FLOWTUSS (hydrocodone bitartrate and guaifenesin)
oral solution contains hydrocodone bitartrate (a centrally-acting
opioid antitussive) and guaifenesin (an expectorant).
Each 5 mL dose of FLOWTUSS contains: hydrocodone bitartrate, USP,
2.5 mg; and guaifenesin, USP, 200 mg.
FLOWTUSS also contains: black raspberry flavor, citric acid, D&C
Red #33, FD&C Blue #1, glycerin, methylparaben, polyethylene glycol,
propylparaben, purified water, saccharin sodium, sodium citrate, and
sorbitol.
Hydrocodone Bitartrate
Guaifenesin
What does Flowtuss look like?
What are the available doses of Flowtuss?
Oral solution: Each 5 mL contains
hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.
()
What should I talk to my health care provider before I take Flowtuss?
How should I use Flowtuss?
FLOWTUSS is indicated for symptomatic relief
of cough and to loosen mucus associated with the common cold.
Important
Limitations of Use:
see Use in Specific Populations
()
Adults and adolescents 18 years of age and older: 10 mL
every 4 to 6 hours, not to exceed 6 doses (60 mL) in 24 hours ()
Measure FLOWTUSS with an accurate milliliter measuring device.
()
What interacts with Flowtuss?
Sorry No Records found
What are the warnings of Flowtuss?
Sorry No Records found
What are the precautions of Flowtuss?
Sorry No Records found
What are the side effects of Flowtuss?
Sorry No records found
What should I look out for while using Flowtuss?
FLOWTUSS is contraindicated in:
p9988316611476059304
Concomitant use of opioids with benzodiazepines
or other central nervous system (CNS) depressants, including alcohol,
may result in profound sedation, respiratory depression, coma, and
death []. Avoid use of opioid cough medications in patients taking
benzodiazepines, other CNS depressants, or alcohol.
What might happen if I take too much Flowtuss?
No human overdosage data are
available for FLOWTUSS.
Hydrocodone
Guaifenesin
Treatment of overdosage consists of discontinuation
of FLOWTUSS together with institution of appropriate therapy. Primary
attention should be given to the reestablishment of adequate respiratory
exchange through provision of a patent airway and the institution
of assisted or controlled ventilation. The opioid antagonist naloxone
hydrochloride is a specific antidote for respiratory depression which
may result from overdosage or unusual sensitivity to opioids including
hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride
should be administered, preferably by the intravenous route, simultaneously
with efforts at respiratory resuscitation. For further information,
see full prescribing information for naloxone hydrochloride. An antagonist
should not be administered in the absence of clinically significant
respiratory depression. Oxygen, intravenous fluids, vasopressors,
and other supportive measures should be employed as indicated. Gastric
emptying may be useful in removing unabsorbed drug.
How should I store and handle Flowtuss?
Carton containing two epinephrine injection, USP auto-injectors 0.3 mg: NDC 0115-1694-49.Carton containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 0115-1694-30.Carton containing two epinephrine injection, USP auto-injectors 0.15 mg: NDC 0115-1695-49.Carton containing one epinephrine injection, USP auto-injector 0.15 mg: NDC 0115-1695-30.Rx onlyCarton containing two epinephrine injection, USP auto-injectors 0.3 mg: NDC 0115-1694-49.Carton containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 0115-1694-30.Carton containing two epinephrine injection, USP auto-injectors 0.15 mg: NDC 0115-1695-49.Carton containing one epinephrine injection, USP auto-injector 0.15 mg: NDC 0115-1695-30.Rx onlyFLOWTUSS (hydrocodone bitartrate and guaifenesin)
oral solution is supplied as a violet-colored, black raspberry flavored
liquid containing 2.5 mg hydrocodone bitartrate and
200 mg guaifenesin in each 5 mL. It is available in: White HDPE bottles of 16 fl. oz. (473 mL): 0178-3482-16
White HDPE bottles of 4 fl. oz. (118 mL): 0178-3482-04 Store solution at 20° to 25°C (68° to
77°F). [See USP Controlled Room Temperature.] Dispense
in a tight, light-resistant container, as defined in the USP, with
a childresistant closure.
×
Clinical Information
Chemical Structure
No Image found
Clinical Pharmacology
Hydrocodone is a semisynthetic narcotic antitussive
and analgesic with multiple actions qualitatively similar to those
of codeine. The precise mechanism of action of hydrocodone and other
opiates is not known; however, hydrocodone is believed to act directly
on the cough center. In excessive doses, hydrocodone will depress
respiration. Hydrocodone can produce miosis, euphoria, and physical
and physiological dependence.
Guaifenesin is an expectorant the action of which promotes or facilitates
the removal of secretions from the respiratory tract. The precise
mechanism of action of guaifenesin is not known; however, it is thought
to act as an expectorant by increasing the volume and reducing the
viscosity of secretions in the trachea and bronchi. In turn, this
may increase the efficiency of the cough reflex and facilitate removal
of the secretions.
Non-Clinical Toxicology
FLOWTUSS is contraindicated in:
p9988316611476059304
Concomitant use of opioids with benzodiazepines
or other central nervous system (CNS) depressants, including alcohol,
may result in profound sedation, respiratory depression, coma, and
death []. Avoid use of opioid cough medications in patients taking
benzodiazepines, other CNS depressants, or alcohol.
Because diethylpropion hydrochloride is a monoamine, hypertension may result when this agent is used with monoamine oxidase (MAO) inhibitors (see
).
Efficacy of diethylpropion with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems; therefore, the concomitant use with other anorectic agents is contraindicated.
Antidiabetic drug requirements (i.e., insulin) may be altered. Concurrent use with general anesthetics may result in arrhythmias. The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, α-methyldopa). Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
Concomitant use of opioids, including FLOWTUSS,
with benzodiazepines, or other CNS depressants, including alcohol,
may result in profound sedation, respiratory depression, coma, and
death. Because of these risks, avoid use of opioid cough medications
in patients taking benzodiazepines, other CNS depressants, or alcohol
[].
Observational studies have
demonstrated that concomitant use of opioid analgesics and benzodiazepines
increases the risk of drug-related mortality compared to use of opioids
alone. Because of similar pharmacologic properties, it is reasonable
to expect similar risk with concomitant use of opioid cough medications
and benzodiazepines, other CNS depressants, or alcohol.
Advise both patients and caregivers about the risks of respiratory
depression and sedation if FLOWTUSS is used with benzodiazepines,
alcohol, or other CNS depressants [].
Use of hydrocodone bitartrate
is associated with the following:
Because clinical trials
are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared
to rates in the clinical trials of another drug and may not reflect
the rates observed in clinical practice.
The most common adverse reactions experienced by subjects taking
a single dose of FLOWTUSS in the clinical setting include the following:
Central Nervous System: headache, dizziness, sedation (somnolence);
Gastrointestinal System: nausea, diarrhea; Cardiovascular System:
decreased blood pressure; Vascular System: hot flush.
×
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Clonazepam Description
Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake.
Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula:
C15H10ClN3O3 M.W. 315.72
×
Tips
Tips
×
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib).
228 major drug interactions (854 brand and generic names)
210 moderate drug interactions (691 brand and generic names)
2 minor drug interactions (4 brand and generic names)
Show all medications in the database that may interact with Imbruvica (ibrutinib).
